Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580463 | 0.81 | NPC1 (0.40) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12075201 | 0.79 | SCD (0.37) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18237571 | 0.79 | TLR8 (0.37) | RAB9ANPC1SMN1; SMN2SCDMAPT | |
| SCHEMBL18857267 | 0.79 | PDPK1 (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12154294 | 0.79 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17786637 | 0.75 | KDM4E (0.38) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL28561318 | 0.74 | SMN1; SMN2 (0.47) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15001036 | 0.74 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2932493 | 0.74 | — | — | |
| SCHEMBL23996116 | 0.73 | PDPK1 (0.35) | SCDPDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-10898474-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20150266899-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| EP-2903991-A1 | ANTI-FIBROTIC PYRIDINONES | Intermune, Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2473510-B1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| WO-2014055548-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-8673933-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | RAB9A 3868/4885NPC1 896/4885SMN1; SMN2 4299/4885 |
| US-10233195-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20150266899-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | JAK2, JAK1, JAK3 | RAB9A 3349/4885NPC1 3223/4885SMN1; SMN2 4359/4885 |
| US-10898474-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | RAB9A 2353/4885NPC1 2565/4885SMN1; SMN2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.